Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Valemetostat in Combination with Lenalidomide and Rituximab for the Treatment of Grade 1-3a Relapsed or Refractory Follicular Lymphoma

Trial Status: active

This phase I/II trial evaluates the safety, best dose, and effectiveness of valemetostat tosylate (valemetostat) in combination with lenalidomide plus rituximab for the treatment of patients with grade 1-3a follicular lymphoma that has come back (relapsed) or that does not respond to treatment (refractory). Valemetostat is an enzyme inhibitor that can reduce proliferation of cancer cells by preventing the expression of genes that are associated with certain cancer pathways. Lenalidomide is a drug that alters the immune system, inhibits the growth of blood vessels that cancer cells use to grow, and promotes death of cancer cells. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. The combination of lenalidomide and rituximab is a Food and Drug Administration-approved treatment for follicular lymphoma. Adding valemetostat to lenalidomide and rituximab may be more effective at treating patients with grade 1-3a relapsed or refractory follicular lymphoma than lenalidomide and rituximab alone.